Get started
Author

Michael Thomas Schweizer

Observed names: M Schweizer, M. Schweizer, M. T. Schweizer, M.T. Schweizer, Michael Schweizer, Michael T Schweizer, Michael T. Schweizer, MichaelT Schweizer, Schweizer, Michael
Observed institutions: Seattle Cancer Care Alliance, Johns Hopkins University, University of Washington, University of Utah, Johns Hopkins Medicine, Huntsman Cancer Institute, Sanofi (France), University of Chicago, Fred Hutch Cancer Center, Cancer Consortium, Housey Pharmaceutical Research Laboratories, VA Puget Sound Health Care System, Marienhospital Stuttgart, University Children's Hospital Tübingen, Brotman Baty Institute, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, PMV Pharmaceuticals, Inc. (United States), University of Tübingen
ORCID: 0000-0002-5510-0661
Observed ORCID: 0000-0002-5510-0661
OpenAlex ID: A5014339741
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
2017 · Eric G. Bluemn, Ilsa M. Coleman, et al. · Cancer Cell · 740
PDF
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
2019 · Mark P. Labrecque, Ilsa M. Coleman, et al. · Journal of Clinical Investigation · 465
Small cell carcinoma of the prostate
2014 · Rosa Nadal, Michael Schweizer, et al. · Nature Reviews Urology · 278
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
2015 · Michael T. Schweizer, Emmanuel S. Antonarakis, et al. · Science Translational Medicine · 254
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
2018 · Daniel Nava Rodrigues, Pasquale Rescigno, et al. · Journal of Clinical Investigation · 203
PDF
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
2017 · Benjamin A Teply, Hao Wang, et al. · The Lancet Oncology · 193
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
2021 · Michael A. Thompson, Jeffrey P. Henderson, et al. · JAMA Oncology · 191
PDF
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
2020 · Kendal Jensen, Eric Q. Konnick, et al. · JAMA Oncology · 168
PDF
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
2019 · Catherine H. Marshall, Alexandra O. Sokolova, et al. · European Urology · 157
MSH2 Loss in Primary Prostate Cancer
2017 · Liana B. Guedes, Emmanuel S. Antonarakis, et al. · Clinical Cancer Research · 156
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
2021 · Samuel R. Denmeade, Hao Wang, et al. · Journal of Clinical Oncology · 136
PDF
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
2014 · Michael T. Schweizer, Xian C. Zhou, et al. · European Urology · 136
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
2020 · Rahul R. Aggarwal, Michael T. Schweizer, et al. · Clinical Cancer Research · 134
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
2018 · Michael T. Schweizer, Kathleen Haugk, et al. · PLoS ONE · 134
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
2020 · Laura S. Graham, Bruce Montgomery, et al. · PLoS ONE · 113
PDF
Microsatellite instability in prostate cancer by PCR or next-generation sequencing
2018 · Jennifer A. Hempelmann, Christina M. Lockwood, et al. · Journal for ImmunoTherapy of Cancer · 113
PDF
Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
2019 · Payel Chatterjee, Michael T. Schweizer, et al. · Journal of Clinical Investigation · 109
PDF
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
2013 · M.T. Schweizer, X.C. Zhou, et al. · Annals of Oncology · 102
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer
2019 · Michael T. Schweizer, Hao Wang, et al. · Stem Cells Translational Medicine · 96
PDF
CDK12 -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade
2020 · Michael T. Schweizer, Gavin Ha, et al. · JCO Precision Oncology · 95
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations
2019 · Michael T. Schweizer, Emmanuel S. Antonarakis, et al. · JCO Precision Oncology · 95
Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone
2014 · Daniel L. Suzman, Brandon Luber, et al. · The Prostate · 93
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
2023 · Erolcan Sayar, Radhika A. Patel, et al. · JCI Insight · 87
PDF
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
2020 · Diana C. DeLucia, Thomas M. Cardillo, et al. · Clinical Cancer Research · 84
PDF
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
2020 · Mark C. Markowski, Hao Wang, et al. · European Urology · 82
Works count: 423
Citation count: 7,262
H-index: 43
I10-index: 105
Year
Topic
Type